Cover Image
市場調查報告書

原發性免疫不全症 (PID) : 開發平台分析

Primary Immune Deficiency (PID) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 229789
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
原發性免疫不全症 (PID) : 開發平台分析 Primary Immune Deficiency (PID) - Pipeline Review, H2 2017
出版日期: 2017年08月08日 內容資訊: 英文 72 Pages
簡介

原發性免疫不全是免疫系統衰弱而不斷引起感染症。同時也容易造成其他健康障礙。症狀有血液感染、肺炎、支氣管炎、鼻竇感染、耳部感染、腦膜炎、皮膚感染疾病、痙攣、食慾不振、噁心和腹瀉等的消化器官障礙。

本報告提供原發性免疫不全症 (PID的)治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

原發性免疫不全症 (PID) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Genethon
  • GlaxoSmithKline plc
  • Green Cross Corporation
  • ProMetic Life Sciences Inc.
  • Sangamo BioSciences, Inc.
  • Sanofi

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (immune globulin (human) + hyaluronidase (recombinant))
  • GC-1112
  • Gene Therapy for Severe Combined Immune Deficiency
  • Gene Therapy for X-Linked SCID
  • Gene Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency
  • GSK-2696273
  • immune globulin (human)
  • immune globulin (human)
  • OT-81
  • plerixafor
  • RI-002
  • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency
  • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency
  • Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9594IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H2 2017, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 2, 8, 1, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 2 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Immune Deficiency (PID) - Overview
    • Primary Immune Deficiency (PID) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Primary Immune Deficiency (PID) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
    • ADMA Biologics Inc
    • Biotest AG
    • Casebia Therapeutics
    • Genethon SA
    • GigaGen Inc
    • GlaxoSmithKline Plc
    • Green Cross Corp
    • Leadiant Biosciences Inc
    • Novartis AG
    • Octapharma AG
    • ProMetic Life Sciences Inc
    • Sangamo Therapeutics Inc
    • Taiga Biotechnologies Inc
    • UCB SA
    • X4 Pharmaceuticals Inc
  • Primary Immune Deficiency (PID) - Drug Profiles
    • aldesleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody for Primary Immune Deficiency Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BT-595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for RAG-Deficient Severe Combined Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elapegademase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for X-Linked SCID - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OTL-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RI-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seletalisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Hematological Disorders and Primary Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Leukocyte Adhesion Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Severe Combined Immunodeficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for X-Linked SCID - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate Artemis for Severe Combined Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Strimvelis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TBX-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-4P001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Primary Immune Deficiency (PID) - Dormant Projects
  • Primary Immune Deficiency (PID) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 23, 2016: Green Cross Receives Complete Response Letter from US FDA for IVIG-SN
      • Aug 09, 2016: ProMetic Completes Adult Patients Enrolment in Pivotal IVIG Phase 3 Clinical Trial
      • Mar 07, 2016: Green Cross Biotherapeutics Receives Health Canada Approval for Phase III Clinical Trials of IVIG 10%
      • Jan 25, 2016: US FDA Accepts Green Cross' Biologics License Application for IVIG-SN
      • Nov 24, 2015: Green Cross Submits Biologics License Application to US FDA for IVIG-SN
      • Oct 26, 2015: Prometic's IVIG IND Cleared By FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Primary Immune Deficiency (PID), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by Casebia Therapeutics, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by Genethon SA, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by Green Cross Corp, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by Leadiant Biosciences Inc, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by Novartis AG, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by ProMetic Life Sciences Inc, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by UCB SA, H2 2017
  • Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H2 2017
  • Primary Immune Deficiency (PID) - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Primary Immune Deficiency (PID), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top